All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What is the role of treatment line and duration in patients with LBCL treated with CAR T cells?

By Dylan Barrett

Share:

Featured:

Stefano LuminariStefano Luminari

Jun 19, 2024


During the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked, What is the role of treatment line and duration in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells?

What is the role of treatment line and duration in patients with LBCL treated with CAR T cells?

First, Luminari highlights the improved outcomes shown with axicabtagene ciloleucel and lisocabtagene maraleucel when compared with standard therapies in the second-line setting, and the clinical implications of these results. He also discusses the impact of the earlier use of CAR T-cell therapy and the importance of identifying patients who have a high risk of relapse who may benefit from timely CAR T-cell therapy. He concludes that CAR T-cell therapy, particularly axicabtagene ciloleucel, represents a major advancement for patients with relapsed LBCL and raises the importance of detecting early signs of relapse.  

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

Your opinion matters

What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?